Effects of brimonidine tartrate 0.2% and 0.15% ophthalmic solution on the static and dynamic pupil characteristics

Abstract

Abstract Purpose: To investigate the differences between 0.2% and 0.15% brimonidine tartrate eye drops for anti-mydriatic effects and the optical quality under different light conditions. Methods This prospective study involved 50 consecutive high myopia patients undergoing implantation of a V4c ICL. 0.2% brimonidine was administered into the right eye, and 0.15% brimonidine was administered into the left eye of the patients 1 month postoperatively. Visual quality (measured by optical quality analysis system), pupil center, pupil size and refraction under different light conditions were measured before and 0.5h after brimonidine administration. A symptom questionnaire was also evaluated. Results There was no statistical difference in the static and dynamic PD and velocity data after LS between the two groups (P>0.05). The 0.2% group had significant changes in pupil center before and after treatment, while there was no obvious movement of the pupil center of the 0.15% group under all illumination condition (P>0.05). The OSI after treatment of the 0.15% group was lower than that of 0.2% group (P=0.012). The PVA9% and PVA100% of the 0.15% group was higher than that of 0.2% group in the dark (P=0.009, P=0.012). The HOA RMS of the 0.15% group was lower than that of 0.2% group (P=0.016). The QIRC score in the 0.15% group was significantly higher than that in the 0.2% group (P=0.043). Conclusion 0.15% and 0.2% brimonidine tartrate eye drops had similar anti-mydriatic ability, while 0.15% group had better visual quality than 0.2% concentration, and hardly introduced pupil shift. 0.15% brimonidine tartrate eye drops may be more suitable for patients with nocturnal glare symptoms in the early postoperative period after ICL implantation.